Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Colorectal Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Colorectal Cancer
    Annual Report Finds Declines in Cancer Incidence and Death in US, But Wide Variation in Lung Cancer Trends - (DGNews)
    TopAbstracts in Colorectal Cancer 11/26/2008 - (DGNews)
    TopAbstracts in Colorectal Cancer 11/12/2008 - (DGNews)
    Imaging Surveillance of Small Polyps, an Alternative to Immediate Colonoscopy - (DGNews)
    TopAbstracts in Colorectal Cancer 10/29/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Colorectal Cancer
  • Treatment of Advanced Colorectal Cancer: What Are the Clinical Implications of Latest Data?
  • Update on Targeted Therapies in mCRC: How to Choose to Maximize Efficacy and Minimize Toxicity
  • Interpreting Current Evidence in mCRC: Progress Towards Individualized Therapy
  • Colorectal Cancer Screening and Prevention

    Webcasts/CME archive

     Recent cases - Colorectal Cancer
      Metastatic Colorectal Cancer to a Primary Thyroid Cancer
      Late Recurrence of Large Peri-Stomal Metastasis Following Abdomino-Perineal Resection of Rectal Cancer
      Cytomegalovirus Colitis in a Patient with Recurrent Colon Cancer After Systemic Chemotherapy: A Case Report
      Solitary Mediastinal Lymph Node Metastasis in Rectosigmoid Carcinoma: A Case Report
      Pulmonary Lymphangitic Carcinomatosis as a Primary Manifestation of Colon Cancer in a Young Adult

      Cases archive
        




      my personal edition > colorectal cancer > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Addition of Oxaliplatin to FOLFIRI Regimen Increases Survival of Patients With Metastatic Colon Cancer: Presented at ASCO-GI

      By Ed Susman

      SAN FRANCISCO, CA -- January 30, 2006 -- Researchers said that the addition of the third cytotoxic anticancer drug oxaliplatin to a standard regimen can extend survival in patients with metastatic colon cancer by 6 months -- to 22.6 months after diagnosis.

      Doctors in the Gruppo Oncologico Nord Ovest in Italy said that by adding oxaliplatin to FOLFIRI (5-fluorouracil and leucovorin with irinotecan) -- creating the combination called FOLFOXIRI -- the gain in survival could be achieved with manageable increases in toxicities.

      "Overall survival improved with FOLFOXIRI with a relative reduction in the risk of death of 30% and absolute improvement in median survival of 5.9 months," said Alfredo Falcone, MD, professor of medical oncology, University of Pisa, Pisa, Italy, at the 42nd Annual Meeting of the American Society of Clinical Oncology - Gastrointestinal Cancer Symposium (ASCO-GI).

      In the trial, the researchers randomly assigned 122 patients to receive FOLFIRI. This regimen includes irinotecan 180 mg/m2 in a 1-hour infusion on the first day of a cycle; leucovorin 100 mg/m2 in a 2-hour infusion on days 1 and 2 of the cycle; 5-FU 400 mg/m2 in a bolus on days 1 and 2; 5-FU 600 mg/m2 in a 22-hour infusion on days 1 and 2. The treatment was repeated every 2 weeks and patients received 12 cycles of treatment.

      A second group of 122 patients were randomly assigned to receive FOLFOXIRI. This regimen included irinotecan 165 mg/m2 on day 1; oxaliplatin 85 mg/m2 on day 1; leucovorin 200 mg/m2 on day 1; 5-FU 3200 mg/m2 by continuous infusion over 48 hours. Each cycle was repeated every 2 week for 12 cycles.

      The researchers defined partial responses as at least a 50% reduction in tumor size.

      About 6% of FOLFIRI patients and 8% of FOLFOXIRI patients experienced complete responses; 35% of the FOLFIRI patients and 58% of the FOLFOXIRI patients achieved partial responses.

      The response rate was 66% in the FOLFOXIRI arm and 41% in the FOLFIRI arm, a difference that reached statistically significance at the P = .0002 level, Dr. Falcone said.

      Disease-free progression average 9.8 months for patients getting oxaliplatin compared with 6.9 months for patients who did not receive this drug. That difference reached statistical significance at the P = .0006 level, Dr. Falcone said.

      Overall survival at 30 months was 34% in the FOLFOXIRI arm and 21% in the FOLFIRI arm, and the median overall survival rates were 22.6 months and 16.7 months, respectively. Those differences also reached statistical significance at the P = .032 level.

      The study protocol allowed patients who progressed on the FOLFIRI regimen to switch to a FOLFOX regimen.

      Dr. Falcone noted that since the study was initiated in November 2001, doctors have begun using the targeted agent bevacizumab in treatment protocols. "I think it would be feasible to add bevacizumab to FOLFOXIRI without a major increase in side effects," he said at a press briefing January 28th, where he discussed his study.

      The symposium is cosponsored by the American Society of Clinical Oncology, the American Gastrointestinal Association, the Society of Surgical Oncology, and the American Society for Therapeutic Radiology and Oncology.


      [Presentation title: Biweekly Irinotecan, Oxaliplatin and Infusional 5FU/LV (FOLFOXIRI) Versus FOLFIRI as First-Line Treatment of Metastatic Colorectal Cancer: Results of a Randomized, Phase III Trial by Gruppo Oncologico Nord Ovest. Abstract 227]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send